What Changed in 2026

FDA Warning Letters: Continued Enforcement

The FDA has continued issuing warning letters to compounding pharmacies in 2026. These are not abstract risks — they are real facilities where real patients received medications.

What inspectors have found:

• Sterile injections being filled on a benchtop table in a room with carpeted floors
• A blood sample centrifuge running in the same room as sterile drug preparation
• Staff wearing non-sterile gloves during aseptic operations with exposed hair and skin
• A facility that approved drugs for distribution even after finding microbial contamination
• A product labeled as 1.25 mg that actually contained 1.75 mg — a 40% dosing error
• An operator with an uncovered skin condition who continued handling sterile products for three months

One pharmacy voluntarily recalled all its sterile products. Another had to recall a lot due to lack of sterility assurance. Additional warning letters have been issued in 2026 beyond the initial three.

Hims Exits Compounded GLP-1 Market

In May 2026, Hims & Hers stopped selling its compounded GLP-1 pill after facing legal pressure from Eli Lilly. This is significant because Hims was one of the highest-profile telehealth companies offering compounded GLP-1s. Their exit signals that the compounded-only telehealth model is contracting as FDA enforcement tightens and brand-name manufacturers defend their patents.

Eli Lilly vs. Empower Pharmacy: Lawsuit Update

Eli Lilly's lawsuit against compounder Empower Pharmacy saw a partial dismissal in April 2026 — some claims were thrown out, but others are proceeding. This case matters because it tests how far brand-name manufacturers can go in suing compounders. A full dismissal would have emboldened compounders; the partial outcome means the legal landscape remains uncertain and risky for compounding pharmacies.

What this means for you: These are not small technical violations. These are conditions that can put contaminated or incorrectly dosed medication into your body.

Enforcement Against Tirzepatide Compounding

The FDA also cited a pharmacy for repackaging compounded tirzepatide (the active ingredient in Mounjaro and Zepbound) under a branded name with added cyanocobalamin. This signals that the FDA is watching tirzepatide compounding too — not just semaglutide.

FDA's June 2026 Consumer Warning Update

The FDA's consumer warning page "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" was last updated June 15, 2026, and it adds detail beyond earlier versions:

• Fraudulent compounded labels. The FDA warns that some products sold as compounded semaglutide or tirzepatide are mislabeled — the vial may not contain what the label claims, or may contain no active ingredient at all. This is separate from the dosing-accuracy problems described above; it's a labeling-fraud risk on top of a manufacturing-quality risk.
• Shipping and storage concerns. The FDA flags that compounded GLP-1 products are temperature-sensitive and that improper shipping or storage (unrefrigerated transit, delays in delivery, at-home storage outside the required temperature range) can degrade the drug or make it unsafe to use. Ask your pharmacy how the product is shipped and what temperature it's kept at in transit.
• Updated adverse-event counts. As of May 31, 2026, the FDA had received roughly 990 adverse-event reports tied to compounded semaglutide products and 730+ tied to compounded tirzepatide products. These counts include reports of hospitalization; the FDA has not attributed all of them specifically to compounding versus the underlying drug class.
• Retatrutide and cagrilintide cannot be legally compounded. The FDA warning page reiterates that retatrutide and cagrilintide are investigational drugs not yet FDA-approved for any use. Under federal compounding law, a drug must be an FDA-approved active ingredient (or meet narrow bulk-substance exceptions) to be compounded — neither retatrutide nor cagrilintide qualifies. Any product marketed as "compounded retatrutide" or "compounded cagrilintide" is being sold outside the law, regardless of what the seller claims.

State-Level Rules Are Growing

More states added their own compounding requirements in 2026:

• Texas and Florida — Additional inspections for compounding pharmacies
• California — Requires patient disclosure that compounded drugs are not FDA-approved
• New York — Proposed new compounding oversight legislation
• Other states are considering similar rules

Check your state's board of pharmacy website for local requirements.

Foundayo: A New FDA-Approved Oral Option

On April 1, 2026, the FDA approved Foundayo (orforglipron) — a daily GLP-1 pill with no food restrictions. This is relevant because:

• Foundayo gives you an FDA-approved oral option that does not require compounding
• It may reduce demand for compounded semaglutide among people who wanted a pill
• Insurance coverage is expanding, which may make it more affordable than compounded options for some patients
• It targets GLP-1 only (not dual-agonist like some compounded products claim)

If you've been using compounded semaglutide because you couldn't afford brand-name, Foundayo is worth checking — especially with Eli Lilly's savings program (as low as $25/month for eligible patients). CVS Caremark also added Foundayo and Zepbound to its national formularies in May 2026, expanding insurance-covered access.

What Is Still Legal

Compounded semaglutide was legal under the FDA's shortage exemption when all three of these conditions were met. That exemption no longer covers semaglutide injection as of May 2026, so condition 1 is not currently satisfied for most pharmacies:

1. The drug is on the FDA shortage list. As of May 2026, semaglutide injection is no longer on the FDA shortage list. Liraglutide remains listed. Without this exemption, shortage-based compounding of semaglutide is not legal — pharmacies are supposed to stop.
2. The pharmacy is licensed and requires a prescription. No prescription = illegal. No license = illegal.
3. The active ingredient matches FDA-approved forms. The pharmacy must use semaglutide base — the same molecule as Ozempic and Wegovy. Salt forms (semaglutide sodium, semaglutide acetate) are different molecules that the FDA has warned against.

Outside the shortage exemption, compounding is only legal under narrower federal rules — for example, a licensed 503A pharmacy customizing a prescription for a documented clinical need (such as a different strength or an allergy-driven formulation change) where the result is not "essentially a copy" of an FDA-approved drug. Standard-dose semaglutide compounded with no individualized clinical reason does not qualify. Ask your pharmacy which legal basis they are using, and verify it independently — do not treat "we're still compounding it" as confirmation that it's legal.

What Is NOT Legal

• Selling compounded semaglutide without a prescription
• Using salt forms instead of semaglutide base
• Calling it "generic Ozempic" or "generic Wegovy" (no FDA-approved generic exists)
• Continuing shortage-based compounding after the exemption ends — semaglutide injection's shortage exemption ended in May 2026
• Repackaging compounded drugs without proper sterile conditions
• Compounding retatrutide or cagrilintide — both are investigational, not FDA-approved for any use, and do not qualify under federal compounding law

Shortage Status: The Big Question

This is the thing that could change everything.

As of May 2026: Semaglutide injection is no longer on the FDA Drug Shortage Database. Liraglutide remains in shortage. This changes the legal landscape significantly — compounding semaglutide is now outside the shortage exemption.

Now that the shortage has ended: Compounding pharmacies are supposed to stop making shortage-based compounded semaglutide. Compliance varies by pharmacy — do not assume a pharmacy that is still selling it has verified its own legal basis for continuing.

What to do: Check the FDA Drug Shortage Database before ordering. If semaglutide is no longer listed, talk to your doctor about switching to an FDA-approved option.

What to Verify Before You Order

Use this checklist. If a pharmacy cannot answer these clearly, find a different one.

The Four Must-Ask Questions

1. "Is this semaglutide base or semaglutide sodium/acetate salt?"

What you want to hear: "Semaglutide base." Red flag: "It's all the same" or "we can't share that."

2. "Are you a 503A or 503B facility?"

What you want to hear: "503B" (higher FDA standards, regular inspections). 503A is not automatically bad — but 503B is safer for injectable medications.

3. "Can I see a certificate of analysis for this lot?"

What you want to hear: "Yes, here it is" — with a document showing potency, purity, and sterility testing from a third-party lab. Red flag: "We do our own testing" or "we don't share that."

4. "Are you licensed in my state?"

What you want to hear: "Yes, here is our license number." Verify it on your state board of pharmacy website.

Price Reality Check

Prices under $200/month for compounded semaglutide are a red flag. The real ingredient costs more than that to source properly.

Now That the Shortage Has Ended: What Happens

This is the scenario behind the "is compounded semaglutide going away?" searches. The FDA removed semaglutide injection from the shortage list in May 2026, which means:

1. Compounding is legally riskier — Pharmacies are supposed to stop, but not every pharmacy will
2. Your supply could disappear — Legitimate pharmacies are more likely to stop; verify before you rely on your current pharmacy
3. Prices might change — Less competition could push remaining options higher

Prepare now: Talk to your doctor about backup options. Check if you qualify for manufacturer savings programs. Many patients can get brand-name for $99-$500/month if they have commercial insurance. And ask about Foundayo — the new FDA-approved pill may be an option.

When to Choose Brand-Name Instead

Compounded semaglutide makes sense when:

• You cannot afford brand-name even with savings programs
• You do not have insurance that covers GLP-1s
• You have verified the pharmacy meets safety standards

Brand-name or Foundayo makes more sense when:

• You have commercial insurance that covers GLP-1s
• You qualify for a savings card (as low as $25/month for Zepbound)
• Your doctor recommends FDA-approved medication
• You want the certainty of tested, regulated medication
• You want a daily pill option (Foundayo)

Supplies You Will Need

Whether you choose compounded or brand-name GLP-1s, these come in handy:

• Alcohol prep pads — for cleaning your skin before each injection
• A sharps container — for safe needle disposal
• Electrolyte powder — for managing nausea and dehydration

GLPSpot may earn from qualifying purchases.

The Bottom Line

Compounded semaglutide is no longer broadly covered by the shortage exemption in 2026 — legality now depends on narrower exceptions, and the landscape is tighter than it was a year ago. The FDA found real safety problems at real pharmacies — carpeted cleanrooms, wrong doses, contaminated products. The FDA's June 15, 2026 warning-page update adds fraudulent labeling and shipping/storage concerns to that list, alongside adverse-event counts that have climbed to roughly 990 reports for compounded semaglutide and 730+ for compounded tirzepatide as of May 31, 2026. New state rules are in effect. Hims stopped selling its compounded GLP-1 pill after legal pressure. Eli Lilly's lawsuit against Empower Pharmacy is partially proceeding. And Foundayo now gives you an FDA-approved pill option with expanding insurance coverage through CVS Caremark.

Check the shortage status. Ask the four questions. Verify the answers. Confirm the active ingredient is FDA-approved (retatrutide and cagrilintide cannot legally be compounded). And always explore brand-name savings programs and Foundayo before assuming compounded is your only option.

This article is for informational purposes only and does not constitute medical or legal advice. Always consult a licensed healthcare provider before starting any medication. Check the FDA Drug Shortage Database for current shortage status. Adverse-event and warning-page details reflect the FDA's consumer warning page, content current as of June 15, 2026.